If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

21 Dec 2015 18:22

RNS Number : 8050J
GW Pharmaceuticals PLC
21 December 2015
 



GW Pharmaceuticals PLC Director/PDMR Shareholding

21 December 2015

 

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

 

Cambridge, UK, 21 December 2015: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has been notified of the following series of transactions in the shares of GW Pharmaceuticals plc.

 

On 18 December 2015 the Company was notified that on 17 December 2015 Mr Cabot Brown, a non-executive Director of the Company, purchased 600 American Depository Shares, or ADS (equivalent to 7,200 ordinary 0.1 pence shares) of GW Pharmaceuticals plc, at a price of $68.864 per ADS (equivalent to 384 pence per share).

 

Following this notification Mr Brown's interest in the shares of GW Pharmaceuticals plc is 7,200 ordinary 0.1 pence shares (equivalent to 600 ADSs), representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Mr. Chris Tovey, a Director and Chief Operating Officer of the Company, exercised options to acquire 24,000 ordinary 0.1 pence shares (equivalent to 2,000 ADSs) of GW Pharmaceuticals plc. These options had an exercise price of 0.1 pence per share. The Company has been notified that on 18 December 2015 these shares, representing less than 0.1% of shares in issue, were converted to 2,000 ADSs and immediately sold at an average price of $67.6275 per ADS (equivalent to 378 pence per share).

 

Following these transactions, Mr. Tovey's beneficial interested in the Company's ordinary 0.1 pence shares is 2,500 shares, representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Dr. Geoffrey Guy, a Director and Chairman of the Company, exercised options to acquire 1,369,848 ordinary 0.1 pence shares (equivalent to 114,154 ADSs) of GW Pharmaceuticals plc. These options had a weighted average exercise price of 41 pence per ordinary 0.1 pence share. The Company has been notified that (1) on 18 December 2015, 1,065,936 of these shares were converted to 88,828 ADSs and immediately sold at an average price of $67.50 per ADS (equivalent to 377 pence per share) and (2) earlier today a further 10,309 ADSs (equivalent to 123,708 ordinary 0.1 pence shares) were sold at an average price of $67.32 per ADS (equivalent to 376 pence per share). Exercise of these options results in an immediate UK income tax liability for Dr. Guy necessitating the immediate sale of a significant number of the resulting shares. In addition, we have been notified that earlier today 6,000 ordinary 0.1 pence shares held by Dr Guy's personal pension scheme were sold at an average price of 366 pence per share.

 

Following these transactions, Dr. Guy's notifiable interest in the ordinary 0.1 pence shares of the Company has increased by 174,204 shares to 14,297,852 shares, representing 5.4% of the Company's current issued share capital.

 

The total number of shares outstanding in the Company is 262,574,021 ordinary 0.1 pence shares.

 

For further information, please contact:

 

GW Pharmaceuticals plc

Adam George, Company Secretary

+44 (0)1980 557 000

Peel Hunt LLP (UK NOMAD)

James Steel

+44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFTFLLLFIE
Date   Source Headline
13th Dec 20104:15 pmRNSDirector/PDMR Shareholding
9th Dec 20102:39 pmRNSPublication of Annual Report
8th Dec 20103:52 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSChange of Adviser
29th Nov 20104:31 pmRNSDirector/PDMR Shareholding
23rd Nov 20107:01 amRNSSativex Enters Phase III Cancer Pain Programme
23rd Nov 20107:00 amRNSFinal Results
19th Nov 201010:10 amRNSUpdate on Nomad and Broker Position
3rd Nov 20107:00 amRNSSativex Approved in New Zealand for MS Spasticity
21st Oct 201011:30 amRNSNotice of Results
21st Oct 201011:30 amRNSNotice of Results
14th Oct 20109:30 amRNSResearch Update
13th Oct 201012:12 pmRNSHolding(s) in Company
30th Sep 20107:03 amRNSGW Starts Phase IIa Study Programme
22nd Sep 20107:00 amRNSSativex Study Results Published in Peer Journal
16th Sep 20109:29 amRNSHolding(s) in Company
16th Sep 20109:28 amRNSHolding(s) in Company
14th Sep 20105:16 pmRNSDirector/PDMR Shareholding
9th Sep 201011:51 amRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHealth Canada Grants Full Approval of Sativex
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding
28th Jul 20107:00 amRNSSativex receives regulatory authorisation in Spain
27th Jul 20107:00 amRNSDirectorate Change
23rd Jul 20105:10 pmRNSDirector/PDMR Shareholding
19th Jul 20103:33 pmRNSDirector/PDMR Shareholding
5th Jul 20105:35 pmRNSDirector/PDMR Shareholding
2nd Jul 201010:03 amRNSResponse to Media Comment
30th Jun 20107:00 amRNSGlobal Cannabinoid Research Collaboration Extended
22nd Jun 201011:23 amRNSGW Pharma to present at Piper Jaffray Conference
21st Jun 20107:00 amRNSUK Launch of First Prescription Cannabis-Medicine
18th Jun 20102:33 pmRNSProduct Update
11th Jun 20103:36 pmRNSDirector/PDMR Shareholding
20th May 20107:00 amRNSInterim Results
11th May 20104:21 pmRNSNotice of Results
28th Apr 20104:40 pmRNSSecond Price Monitoring Extn
28th Apr 20104:35 pmRNSPrice Monitoring Extension
31st Mar 20105:28 pmRNSTotal Voting Rights
25th Mar 20104:07 pmRNSDirector/PDMR Shareholding
24th Mar 20105:21 pmRNSHolding(s) in Company
24th Mar 20102:55 pmRNSResult of AGM
23rd Mar 20103:44 pmRNSHolding(s) in Company
23rd Mar 20103:38 pmRNSHolding(s) in Company
23rd Mar 20107:00 amRNSPositive Data in Sativex Phase IIb Trial
18th Mar 20107:00 amRNSSativex Regulatory Update
18th Jan 20105:27 pmRNSBlock Listing Application
15th Jan 201011:09 amRNSTotal Voting Rights
5th Jan 20104:35 pmRNSPrice Monitoring Extension
11th Dec 20098:57 amRNSDoc re. Annual Report
1st Dec 20097:00 amRNSChange of Adviser
26th Nov 20095:46 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.